Epilepsy is one of the most frequent severe brain disorders, impacting about 70 million individuals globally. Its prevalence is bimodal, with neonates and the elderly suffering the highest risk. Whether using medications or not, nearly two out of every three individuals suffering from new-onset epilepsy will achieve long-term seizures remission, although around half will experience mild to moderately severe side effects. Patients with epilepsy, mainly the 20-30percent of the respondents whose seizures are not fully controlled by present treatments (drug-resistant epilepsy), have a significantly increased risk of death, mental and physical comorbidities, and severe pharmaceutical effects. Here we present a case of 56-year-old man who was admitted to a private hospital and diagnosed with a rare type of epilepsy. He was unconscious, hence reported as comatose state. Mental diseases, such as depression, have also been predominantly studied in our patients, although there was a rising acknowledgment of a bidirectional association between the epilepsy and depression. The patient has been introduced to pregabalin 75mg once to rouse from a comatose state. Following this regime, he was declared conscious and alive. He was discharged and continued to pregabalin 75mg daily until the next follow-up. Pregabalin was found to be a significant addition to the treatment of epilepsy because of its effective antiseizure action, favorable pharmacokinetic properties, and efficacy in frequent co-morbidities. Antiepileptic drug development must be resuscitated rapidly in order to identify new effective anti-seizure medications for the treatment of drug-resistant epilepsy International health practitioners may continue the further investigation related to the onset of this condition to reach significant evidence and treatment.